Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis c treatments: An exploratory study

Psychology, Health and Medicine

Volumn 18, Issue 6, 2013, Pages 742-750

  Hopwood, Max ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

hepatitis C virus infection; pegylated interferon and ribavirin; persistent neurotoxicity; treatment outcomes

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; AFTERCARE; ANOREXIA; ARTICLE; AUSTRALIA; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COGNITIVE DEFECT; DEPRESSION; FEMALE; HEALTH PERSONNEL ATTITUDE; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; QUALITY OF LIFE; RECURRENT DISEASE; SARCOIDOSIS; SELF REPORT; SEVERITY OF ILLNESS INDEX; STANDARD; TOXICITY AND INTOXICATION; TREATMENT OUTCOME; CHEMICALLY INDUCED; COGNITION DISORDERS; NEUROTOXICITY SYNDROMES; PSYCHOLOGY; STANDARDS;

ADULT; AFTERCARE; ANOREXIA; ANTIVIRAL AGENTS; ATTITUDE OF HEALTH PERSONNEL; CHRONIC DISEASE; COGNITION DISORDERS; DEPRESSION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; NEW SOUTH WALES; PATIENT EDUCATION AS TOPIC; QUALITATIVE RESEARCH; QUALITY OF LIFE; RECURRENCE; RIBAVIRIN; SARCOIDOSIS; SELF REPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VICTORIA;

EID: 84886728607     PISSN: 13548506     EISSN: None     Source Type: Journal    
DOI: 10.1080/13548506.2013.774429     Document Type: Article

References (19)

1. Aronsohn, A., & Reau, N. (2009). Long-term outcomes after treatment with interferon and ribavirin in HCV patients. Journal of Clinical Gastroenterology, 43, 661-671.doi: 10.1097/MCG.0b013e31819f66e2
2. Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3, 77-101.doi: 10.1191/1478088706qp063oa
3. Commonwealth of Australia (2010). Third National Hepatitis C Strategy 2010-2013.Australian Government Department of Health and Ageing. Retrieved from http://www.health.gov.au/internet/main/publishing.nsf/Content/ ohp-national-strategies-2010-hcv/$File/hcv.pdf
4. Dieperink, E., Ho, S.B., Thuras, P., & Willenbring, M.L. (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics, 44, 104-112.Retrieved from http://dx.doi.org/10.1176/appi.psy. 44.2.104
5. Fried, M.W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36 (Suppl. 1), 237-244.doi: 10.1053/jhep. 2002.36810
6. Gayet, A.R., Plaisance, P., Bergmann, J.F., & Mouly, S. (2010). Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-2a and ribavirin: A case report and literature review. Clinical Medicine and Research, 8, 163-167.doi: 10.3121/cmr.2010.886
7. Hepatitis NSW Inc (2011). Glen's story: Dealing with deniers. Hep Review, 73, 46. Retrieved from http://hepmagazines.realviewtechnologies.com/?xml=Hep-C- Review & iid=48766
8. Hepatitis NSW Inc (2010). Treatment side effects: Mental. Hepatitis C Factsheets, 1-4.Retrieved from http://www.hep.org.au/documents/factsheets/ TreatmentSideEffectsMental2010.pdf
9. Hopwood, M., & Treloar, C. (2007). Pre-treatment preparation and management of interferonbased therapy for hepatitis C virus infection. Journal of Advanced Nursing, 59, 248-254.doi: 10.1111/j.1365-2648.2007.04305.x
10. Jensen, D.M. (2011). A new era of hepatitis C therapy begins [Editorial]. New England Journal of Medicine, 364, 1272-1274. doi: 10.1056/NEJMe1100829
11. Lawrence, C. (2011, March). Chris' story: Dealing with the after-effects. Hepatitis Review, 72, 46. Retrieved from http://hepmagazines. realviewtechnologies.com/?xml=Hep-C-Review&iid= 46790
12. McNally, S., Temple-Smith, M., & Pitts, M. (2005). Making decisions about hepatitis C treatment [Report No. 49]. Melbourne: The Australian Research Centre in Sex, Health and Society, La Trobe University. Retrieved from http://www.latrobe.edu.au/arcshs/downloads/arcshs-researchpublications/ making-decisions-about-hepc-treatment.pdf
13. Meyers, C.A., Scheibel, R.S., & Forman, A.D. (1991). Persistent neurotoxicity of systematically administered interferon-alpha. Neurology, 41, 672-676
14. Raison, C.L., Demetrashvili, M., Capuron, L., & Miller, A.H. (2005). Neuropsychiatric adverse effects of interferon-alpha: Recognition and management. CNS Drugs, 19, 105-123.doi: 1172-7047/05/0002-0105/$34.95/0
15. Reichenberg, A., Gorman, J.M., & Dieterich, D.T. (2005). Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. AIDS, 19 (Suppl. 3), 174-178
16. St. John, T.M., & Sandt, L. (2005). The hepatitis C crisis. Ethnicity and Disease, 15(Suppl. 2), 52-57.
17. Tomer, Y. (2010). Hepatitis C and interferon induced thyroiditis. Journal of Autoimmunity, 34, 322-326. doi: 10.1016/j.jaut.2009.11.008
18. Treloar, C., & Hopwood, M. (2008). "Look, I'm fit, I'm positive and I'll be all right, thank you very much": Coping with hepatitis C treatment and unrealistic optimism. Psychology, Health and Medicine, 13, 360-366. doi: 10.1080/13548500701477532
19. Ware, J.E.Jr., Bayliss, M., Mannocchia, M.S., Davis, G.L., & the International Hepatitis Interventional Therapy Group (1999). Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology, 30, 550-555.